The drug is used to treat muscle spasms and pain alongside physical therapy and rest. The recalled lots of orphenadrine citrate ER tablets were shipped to customers from August 2019 to April 2021.
“Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits,” the company said. “While the use of product belonging to the recalled lots may present a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.”
Sandoz, Novartis’ generic drug unit, said it has started contacting wholesalers and distributors and is arranging for the return of recalled products.
To view details of the recalled lots, click here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.